Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001327727 | SCV001518814 | likely benign | Saldino-Mainzer syndrome | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002486323 | SCV002787325 | uncertain significance | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2022-02-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003169540 | SCV003867964 | uncertain significance | Inborn genetic diseases | 2023-02-22 | criteria provided, single submitter | clinical testing | The c.2407G>A (p.V803I) alteration is located in exon 20 (coding exon 18) of the IFT140 gene. This alteration results from a G to A substitution at nucleotide position 2407, causing the valine (V) at amino acid position 803 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004692517 | SCV005194101 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003405554 | SCV004115276 | uncertain significance | IFT140-related disorder | 2024-07-03 | no assertion criteria provided | clinical testing | The IFT140 c.2407G>A variant is predicted to result in the amino acid substitution p.Val803Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.023% of alleles in individuals of Latino descent with one homozygote in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |